MX2021008263A - Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. - Google Patents

Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Info

Publication number
MX2021008263A
MX2021008263A MX2021008263A MX2021008263A MX2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A
Authority
MX
Mexico
Prior art keywords
sub
methods
receptor
conditions related
treating conditions
Prior art date
Application number
MX2021008263A
Other languages
English (en)
Inventor
Snehal Naik
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2021008263A publication Critical patent/MX2021008263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

Se proporcionan métodos para seleccionar individuos para el tratamiento con ácido (R)-2-(7-(4- ciclopentil-3-(trifluorometil)b enciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético (Compuesto 1) o una sal, hidrato o solvato farmacéuticamente aceptable de este.
MX2021008263A 2019-01-08 2020-01-08 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. MX2021008263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
MX2021008263A true MX2021008263A (es) 2021-10-13

Family

ID=69467760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008263A MX2021008263A (es) 2019-01-08 2020-01-08 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Country Status (10)

Country Link
US (1) US20220142977A1 (es)
EP (1) EP3908276A1 (es)
JP (1) JP2022516662A (es)
KR (1) KR20210113298A (es)
CN (1) CN113874009A (es)
AU (1) AU2020206700A1 (es)
CA (1) CA3124701A1 (es)
IL (1) IL284114A (es)
MX (1) MX2021008263A (es)
WO (1) WO2020146529A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
US20210386706A1 (en) * 2018-10-03 2021-12-16 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030424T2 (en) 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
EP3242666A1 (en) * 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Also Published As

Publication number Publication date
AU2020206700A1 (en) 2021-07-15
CA3124701A1 (en) 2020-07-16
IL284114A (en) 2021-08-31
US20220142977A1 (en) 2022-05-12
KR20210113298A (ko) 2021-09-15
WO2020146529A1 (en) 2020-07-16
CN113874009A (zh) 2021-12-31
EP3908276A1 (en) 2021-11-17
JP2022516662A (ja) 2022-03-01

Similar Documents

Publication Publication Date Title
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
CR20220258A (es) Inhibidores de kras g12c
MX2021000310A (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de las enfermedades que dependen de la familia de dedo de zinc ikaros (ikzf2).
CR20210001A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2)
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
EP3310760B8 (en) Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
WO2008130879A3 (en) Tetrahydroindole and tetrahydroindazole derivatives
WO2008157751A3 (en) Substituted imidazoheterocycles
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2021013531A (es) Inhibidores de cdk.
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
EP3957631A4 (en) QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF EWING'S SARCOMA
WO2019175799A3 (en) Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
EA200870454A1 (ru) Способ ингибирования c-kit киназы
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
JP2017525717A5 (es)
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
WO2010068520A3 (en) Substituted imidazoheterocycle derivatives
WO2016023028A3 (en) G protein-coupled receptor kinase 2 inhibitors and methods for use of the same